Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

57.71
+10.9223.34%
Post-market: 57.31-0.4050-0.70%19:59 EST
Volume:7.07M
Turnover:395.13M
Market Cap:7.84B
PE:-4.73K
High:59.15
Open:47.39
Low:45.09
Close:46.79
52wk High:59.15
52wk Low:9.57
Shares:135.81M
Float Shares:118.91M
Volume Ratio:2.06
T/O Rate:5.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0122
EPS(LYR):-0.0122
ROE:8.67%
ROA:4.87%
PB:16.82
PE(LYR):-4,733.04

Loading ...

Arrowhead trading halted, news pending

TIPRANKS
·
Nov 19

REGN, GMAB, ARWR: Which Healthcare Stock Is Best Buy Ahead of U.S. Drug Approvals This Nov?

TIPRANKS
·
Nov 13

Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says

MT Newswires Live
·
Nov 13

Morgan Stanley Raises Price Target on Arrowhead Pharmaceuticals to $45 From $29, Keeps Equalweight Rating

MT Newswires Live
·
Nov 12

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

Benzinga_recent_news
·
Nov 11

Press Release: Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

Dow Jones
·
Nov 07

Arrowhead Pharmaceuticals to Present Fazirsiran Data at AASLD The Liver Meeting

Reuters
·
Nov 04

Arrowhead Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Oct 29

Arrowhead Pharmaceuticals Grants 127,230 Restricted Stock Units to New Employees

Reuters
·
Oct 29

Arrowhead Pharmaceuticals Advances ARO-DM1 Study for Myotonic Dystrophy

TIPRANKS
·
Oct 28

B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $61 From $38, Keeps Buy Rating

MT Newswires Live
·
Oct 22

Arrowhead Pharmaceuticals (ARWR) Gets a Buy from B. Riley Securities

TIPRANKS
·
Oct 22

BRIEF-Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Reuters
·
Oct 21

Why Arrowhead Pharmaceuticals (ARWR) Is Up 5.9% After First-in-Class Dual Gene RNAi Trial Filing

Simply Wall St.
·
Oct 17

Arrowhead Pharmaceuticals Files Amendment to Annual Report

Reuters
·
Oct 11

RBC Capital Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Oct 10

Arrowhead Pharmaceuticals (ARWR): Valuation Insights Following First-in-Class RNAi Therapy Trial Application

Simply Wall St.
·
Oct 10

Arrowhead Pharmaceuticals (ARWR) Is Up 5.9% After Filing for First Dual-Gene RNAi Therapy Trial – Has the Long-Term Thesis Shifted?

Simply Wall St.
·
Oct 08

RBC Raises Price Target on Arrowhead Pharmaceuticals to $45 From $38, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Oct 08

H.C. Wainwright Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Oct 08